NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced key milestones in its two late-stage therapeutic development programs, vilazodone and Stedivaze (apadenoson). The Company reported that it has completed enrollment in the second Phase III registration trial of vilazodone for the treatment of major depression. Additionally, Clinical Data recently conducted an end of Phase II meeting with the U.S. Food and Drug Administration (FDA) for its cardiac stress imaging agent, Stedivaze, now poised to enter Phase III studies for cardiac perfusion testing. As a result, the Company is well positioned to achieve its anticipated 2009 milestones for both the vilazodone and Stedivaze Phase III clinical programs.
